LV12150B - Farneziltransferāzes inhibitori - Google Patents
Farneziltransferāzes inhibitori Download PDFInfo
- Publication number
- LV12150B LV12150B LVP-98-129A LV980129A LV12150B LV 12150 B LV12150 B LV 12150B LV 980129 A LV980129 A LV 980129A LV 12150 B LV12150 B LV 12150B
- Authority
- LV
- Latvia
- Prior art keywords
- tetrahydro
- imidazol
- ylmethyl
- benzodiazepine
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (17)
1LV 12150 Izgudrojuma formula . Savienojums ar formulu (I), (II), (III) vai (IV) r4,rs Γ^ρ A„ <££-Rr-Ss-T,-^-N , N-2-R8 ' \R7^N V/ v7m w R,R,R a1 d2 d3 Vc *Ol»x r1,r2,r3 2 JQLRr.Ss-T,-^(ln N-r5,rj/n ΧάΛm 'T*®" N—Z—R8 r\r2,r3 I-2-R8 J&*rs.^rr-K% r6r7/N V/ W R1,R2,R3 2 tā enantiomēri, diastereomēri un farmaceitiski pieņemamās sālīs, zāļu priekštečvielas un solvāti, kas inhibē farnezilproteīntransferāzi, fermentu, kurš piedalās ras onkogēna ekspresijā, ar šādām augstāk minēto apzīmējumu nozīmēm: m, n, r, s un t ir 0 vai 1; V, W un X ņemti no rindas, kas ietver skābekļa atomu, ūdeņraža atomu, R1, R2 un R3; Z un Y ņemti no rindas, kas ietver CHR9, SO2, S03, CO, C02, O, NR10, so2nr1Vconr12, n-cn n-cn 0 II II II —C— / —C-N— R13 / —N—C— / —N-S02— / R14 R1® 0 II —C-N-N— r16r17 - / -so2-ņ-ņ— / o^m20 R21N NR22 r18r19 -S- / —S — pie kam Z nav obligāts; R® D7 D® r12 q13 p14 p16 p1? R^® p19 p20 p21 p22 p24 p25 Γ\ ] Γ\ ι Γ\ ļ Γλ ι Γ\ ι i\ j Γλ ļ Γ\ ļ η ļ γ> ι Γλ ι ι% ι γ\ ι ι\ ι Γ\ ι ι\ f η y r% ι R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37 un R38 ņemti no rindas, kas ietver ūdeņraža atomu, zemāko alkilgrupu, aizvietotu alkilgrupu, arilgrupu un aizvietotu arilgrupu; R4 un R5 ir ņemti no rindas kas ietver ūdeņraža atomu, halogēna atomu, nitrogrupu, ciāngrupu un U-R , U ir ņemts no rindas, kas ietver sēra atomu, skābekļa atomu, NR24, CO, SO, S02, C02l NR25C02, nr2Sconr27, nr28šo2, nr29so2nr30, S02NR31, NR32CO, CONR33, PO2R34 un PO3R35, pie kam U nav obligāts; R1, R2 un R3 ir ņemti no rindas, kas ietver ūdeņraža atomu, alkilgrupu, alkoksikarbonilgrupu, aizvietotu alkilgrupu, alkenilgrupu, aizvietotu alkenilgrupu, alkinilgrupu, aizvietotu alkinilgrupu, aralkilgrupu, cikloalkilgrupu, arilgrupu, aizvietotu arilgrupu, heterociklisku grupu, aizvietotu heterociklisku grupu, ciāngrupu, karboksilgrupu, karbamilgrupu (proti, CONH2) un aizvietotu karbamilgrupu, kas var būt alkilkarbamilgrupa, arilkarbamilgrupu, aralkilkarbamilgrupa vai divaizvietota karbamilgrupa, kuras aizvietotāji ņemti no rindas: alkilgrupa, arilgrupa un aralkilgrupa; R8 un R23 ir ņemti no rindas, kas ietver ūdeņraža atomu, alkilgrupu, alkenilgrupu, aizvietotu alkenilgrupu, alkinilgrupu, aizvietotu alkinilgrupu, aralkilgrupu, cikloalkilgrupu, arilgrupu, aizvietotu arilgrupu, heterociklisku grupu un aizvietotu heterociklisku grupu; 3 LV 12150 pie tam jebkuri divi no aizvietotājiem R1, R2 un R1 var but savienoti, veidojot cikloalkilgrupu; R, S un T ir ņemti no rindas, kas ietver CH2, CO un CH(CH2)PQ, kur Q ir NR36R37, OR38 vai CN; A, B, C un D ir oglekļa, skābekļa, sēra vai slāpekļa atomi; ar tādu noteikumu: 1. kad m ir 0, tad V un W abi vienlaikus nav skābekļa atoms; 2. formulās (I) un (II) V un W abi vienlaikus var būt skābekļa atoms tikai tad, kad Z nav, vai tas ir O, NR10, CHR9, o 11 —n—c—- / vai —N-S02- R14 R15 formulās (III) un (IV) V un X abi vienlaikus var būt skābekļa atoms tikai tad, kad Y ir 0, NR10, CHR9, o 11 —n—c— / vai —Ņ’S02— R14 R15 -N-S 02 R15 O NR20 / ->sČ- R21N NR22 / -$>*-
2. Savienojums pēc 1. punkta, kas ņemts no rindas r2,rs
OR r4,rs
Π N-Z-m w / R1,RZ,R1 1 R23 nevar būt ūdeņraža atoms tad, kad U ir SO, S02, NR25C02 vai NR28S02; 2 R8 nevar būt ūdeņraža atoms tad, kad Z ir S02, C02 vai 4
3. Savienojums pēc 2. punkta, kurā m ir nulle un ABCD ir karbocikls.
4. Savienojums pēc 3. punkta, kurā karbocikls ir benzola gredzens.
5. Savienojums pēc 1. punkta, ar formulu (I),
kurā m ir nulle un ABCD ir karbocikls.
6. Savienojums pēc 5. punkta, kurā karbocikls ir benzola gredzens.
7. Savienojums pēc 1. punkta, kas ņemts no rindas: 2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-(1 -naftoil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 8-hlor-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-1H-1,4-benzo-diazepīna hidrogēnhlorīds; 1.2.3.4- tetrahidro-4-(3H-imidazol-4-ilmetil)-1-(1-naftoil)hinoksalīna dihidrogēn-hlorīds; 2.3.4.5- tetrahidro-4-(1 H-imidazol-4-ilmetil)-1-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-iimetil)-2-metil-4-(1-naftoil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-4-(1-naftoil)-1-(1-fenilmetil-1H-imidazol-5-ilmetil)-1,4-benzo-diazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-(1 H-imidazol-4-ilmetil)-4-(1-naftalīnsulfonil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (S)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-2-(metiltioetii)-4-(1-naftoil)-1H-1,4-benzodiazepīna hidrogēnhlorīds; 5 LV 12150 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-N-metil-N-fenil-4H-1,4-benzo-diazepīn-4-karboksamīda hidrogēnhlorīds; 2-[2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-1 H-1,4-benzodiazepin-4-il]-sulfonil)benzoskābes metilestera hidrogēnhlorīds; 7-brom-2,3,4l5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-1H-1,4-benzo-diazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-2-ilmetil)-4-(1-naftoil)-7-fenif-1 H-1,4-benzo-diazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-2-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-[3-(1 H-imidazol-2-il)propil]-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 1-[3-amino-3-(1 H-imidazol-2-il)propil]-2,3,4,5-tetrahidro-4-(1-naftoil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-metil-4-(1-naftoil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (S)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-[2-(metiltio)etil]-4-(1-naftoil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-9-metil-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-4-(1 H-imidazol-4-ilmetil)-9-metil-1-(1 -naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 1{[2-(2-aminoetii)-1 H-imidazol-4-il]metil}-2,3,4,5-tetrahidro-4(1-naftoil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 1 {[(2-aminometil)-1 H-imidazol-4-il]metil}-2,3,4,5-tetrahidro-4(1-naftoil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzo-diazepin-8-il]acetamīda dihidrohlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-pirido[2,3-e]-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-nafto[2,3-e]-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-8-nitro-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 213.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-8-amino-1 H-1,4-benzo-diazepīna dihidrogēnhlorīds; N-[2,3l4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-1H-1,4-benzo-diazepin-8-il]benzamīda dihidrohlorīds; N-[2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-1H-1,4-benzo-diazepin-8-il]cikloheksānkarboksamīda dihidrohlorīds; 2.3.4.5- tetrahidro-1-[2-(1H-imidazol-4-il)etil]-4-(1-naftoil)-1H-1,4-benzo-diazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-[2-(1 H-imidazol-4-il)etil]-4-(1-naftoil)-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-brom-2,3,4,5-tetrahidro-1-[2-(1H-imidazol-4-il)etil]-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 1{[(2-aminometil)-1H-imidazol-5-il]metil}-2,3,4,5-tetrahidro-4(1-naftoil)-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 6 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-1H-1,4-benzo-diazepīn-4-karbonskābes fenilmetilesteris; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilrnetil)-7-fenil-4-(2-trifluormetoksibenzoii)-1H-1,4-benzodiazepīns; 1.2.3.5- tetrahidro-1-{1 H-imidazol-4-ilmetil)-N-metil-N,7-difenil-4H-1,4-benzo-diazepīn-4-karboksamīda dihidrogēnhlorīds; 2,3A5-tetrahidro-1-(1H-imidazol-4-ilrnetil)-4-(1-naftoil)-7-(1-piperidinilsulfonil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-7-piridin-2-ii-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 7-(2-furanil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-7-(2-tienil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-(1 -naftoil)-7-(4-piridinil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-[3-(1H-imidazol-2-il)propil]-4-{1-naftoil)-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7- brom-2,3,4,5-tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 8- hlor-2,3,4,5-tetrahidro-4-(1 H-imidazol-4-iImetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-7-fenil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1,4-bis(1 H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-4-(1 H-imidazol-4-Hmetil)-4-(1-naftilmetil)-7-fenil-1 H-1,4-benzodiazepīna trifluoracetāts; 2.3.4.5- tetrahidro-4-(1 H-imidazol-4-ilmetil)-7-metoksi-4-(1-naftoil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-7-fenil-1 H-1,4-benzo-diazepīn-7-karbonskābes dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-5-ilmetil)-4-(1-naftoil)-7-cikloheksil-1 H-1,4-benzodiazepīns.2,5 HCI; 7-butil-2,3,4,5-tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 1{[(2-aminoetil)-1H-imidazol-4-il]metil}-2,3,4,5-tetrahidro-4-(1-naftoil)-7-fenil-1H-1,4-benzodiazepīna trihidrogēnhlorīds; 1{[(2-aminometil)-1H-imidazol-4-il]metil}-2,3,4,5-tetrahidro-4-(1-naftoil)-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-8-[N,N-bis(fenilmetil)-amino]-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1-(1 H-irnidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzo-diazepin-8-il]fenilsuifonamīda dihidrogēnhlorīds; N-fenil-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzo-diazepīn-7-karboksamīda dihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-(1 -naftoil)-1 H-1,4-benzo-diazepin-8-il]-3-metilbenzamīda dihidrogēnhlorīds; 7 LV 12150 N-[2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-1H-1,4-benzo-diazepin-8-il]-4-metilbenzamīda dihidrogēnhlorīds; 3- hlor-N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzo-diazepin-8-il]benzamīda dihidrogēnhlorīds; 7-brom-2,3,4,5-tetrahidro-1-{[2-(dimetilaminometil)-1H-imidazol-4-il]metil}-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-(4-hlorfenil)-2,3,4,5-tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-(3-aminofenil)-2,3,4,5-tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 1 -metil-N-[2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmeti 1)-4-(1 -naftoil)-1 H-1,4-benzodiazepin-8-il]-1H-pirol-2-karboksamīda trihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzo-diazepin-8-il]-furān-3-karboksamīda dihidrogēnhlorīds; 7-(3-hlorfenil)-2,3,4,5-tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2-metil-N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepin-8-il]benzamīda dihidrogēnhlorīds; N-fenil-N’-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepin-8-il]urīnvielas dihidrogēnhlorīds; 7-(3-piridinil)-2,3,4,5-tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-4-(1 H-imidazol-4-ilmetil)-9-metoksi-4-(1 -naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1 -naftoil)-7-fenil-1 H-pirido[2,3-e]- 1.4- diazepīna trihidrogēnhlorīds; (R) -2,3,4,5-tetrahidro-1-{1H-imidazol-4-ilmetil)-3-(2-metiltioetil)-4-(1-naftoil)-1H- 1.4- benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-3-(2-hidroksietil)-1 H-1,4-benzodiazepīna trifluoracetāts; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-(2-metiltioetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīna trifluoracetāts; (S) -2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts; 4- acetil-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-3-fenilmetii-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-4-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-3-fenilmetil-1 H-1,4-benzodiazepīns.1,5 HCI; 7-brom-1,2,3,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetiI-4H-1,4-benzo-diazepīn-4-karboksamīda trifluoracetāts; 7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 4-acetil-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts; 4-acetil-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-iimetii)-3-[(4-hlorfenil)metil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 8 4-aceti 1-2,3,4,5-tetra h id ro-1 -(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-nafto-[2,3-e]-1,4-diazepīna hidrogēnhlorīds; N-cikloheksil-N’-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepin-8-il]urīnvielas dihidrogēnhloffds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-3-fenilmetil-1H-1,4-nafto[2,3-e]-1,4-diazepTna hidrogēnhlorīds; 2,2-dimetil-N-[2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-(1 -naftoil)-1 H-1,4-benzodiazepin-8-il]propānamīda dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftafīnsūlfonil)-7-fenil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 4-acetil-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(2-naftilmetil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 4-acetil-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-iimetil)-3-(1-naftilmetil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 7- (2-hlorfenil)-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetiI)-4-(1-naftoiI)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 1-metil-N-[2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-naftoil)-1H-1,4-benzodiazepin8-il]-2-piperidīnkarboksamīda trihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzo-diazepin-8-il]-4-morfofīnkarboksamīda dihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzo-diazepin-8-il]-3-metilbutānamīda dihidrogēnhlorīds; 1.2.3.4- tetrahidro-4-(1H-imidazol-4-ilmetil)-1-(naftalīn-1-sulfonil)hinoksafīna dihidrogēnhlorīds; 1.2.3.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-N,N,7-trifenil-4H-1,4-benzodiazepīn-4-karboksamīda dihidrogēnhlorīds; 1.2.3.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-4H-nafto[2,3-e]-1,4-diazepīn-4-karbonskābes metilestera hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-[(4-fenil-1,2,3-tiadiazol-5-il)karbonil]-1 H-1,4-benzodiazepīna trifluoracetāts; 8- [(cikloheksilaminokarbonil)amino]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)- 3- fenilmetil-1 H-1,4-benzodiazepīn-4-karbonskābes 1,1 -dimetiletilesteris; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-8-[(4-metilfenil)sulfonilamino]-3-fenilmetil-1 H-1,4-benzodiazepīn-4-karbonskābes 1,1 -dimetiletilesteris; 7-brom-1,2,3,4-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-5H-1,4-benzo-diazepin-5-ona dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[1-okso-3-(1-piperidinil)propil]-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetra h id ro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(4-hinolinilkarbonil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 4- [(5-brom-3-piridinil)karbonil]-2,3r4,5-tetrahidro-1-(1H-imidazol-4-iImetil)-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; (S)-4-(2-dimetilamino-1-okso-3-fenilpropil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-4-[4-hidroksi-3-(4-morfolinilmetil)benzoil]-1-(1H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 9 LV 12150 (S)-2,3>4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-[(1-metil-2-pirolīdinil)karbonil]-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-{[2-(propiltio)-3-piridinilļ-karbonil}-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 4-[(2-hlor-6-metil-4-piridinil)karbonil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(2-feniltio-3-piridinil)-karbonil]-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-{[2-(4-metilfenoksi)-3-piridinil]-karbonil}-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(2-metoksi-3-piridinii)karbonil]-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(4-fenil-5-oksazolil)karbonil]-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 4-acetil-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzo-diazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(tetrahidro-3-furanil)-karbonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(2-metoksietoksi)acetil]-7-fenil-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[4-(4-morfolinilmetil)benzoil]-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilrnetil)-4-(4-metilsulfonilbenzoil)-7-fenil-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(1-okso-3-feniIsulfonilpropil)-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-piridinilacetil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.314.5- tetrahidro-1-(1H-iimidazol-4-ilmetil)-7-fenil-4-(2-hinoksalinilkarbonil)-1H- 1.4- benzodiazepīna tetrahidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(4-izohinolinilkarbonil)-1H- 1.4- benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(2-hlor-3-piridinil)karbonil]-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-piridinilkarbonil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(2,6-dimetoksi-3-piridinil)-karbonil]-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-pirazinilkarbonil)-1 H-1,4-benzodiazepīna tetrahidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-etoksibenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(3-dimetilaminobenzoil)-1H- 1.4- benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-iimetil)-7-feni!-4-[(1 -feniiciklopropil)-karbonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(biciklo[4.2.0]okta-1,3,5-trien-7-il)karbonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 10 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-benzoil-1 H-1,4-benzo-diazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-hlorbenzoil)-1 H-1,4-benzodiazepma dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2,3-dihlorbenzoil)-1H-1,4-benzodiazepTna dihidrogēnhlorīds; N-(2-{[2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepin-4-il]karbonil}fenil)acetamīda dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-fenoksibenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-{2-metoksibenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2,3-dimetoksibenzoil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil~4-(2,4-dimetoksibenzoil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2,5-dimetoksibenzoil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(2,6-dimetoksibenzoil)-1 H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2,3-dihidroksibenzoil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 4-[(1,1 '-bifenil)-2-ilkarbonilļ-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-metilbenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2,3-dimetilbenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-ciānbenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-hlorbenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-fenoksibenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-metoksibenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-{3,4-dimetoksibenzoil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(3,5-dimetoksibenzoil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-feniI-4-(3-metilbenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(1,2-diokso-2-feniletil)-1 H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-etoksi-1-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-naftoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(4-fluorfenilacetil)-1 H-1,4-benzodiazepma dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-difenilacetil-1 H-1,4-benzo-diazepīna dihidrogēnhlorīds; 2.314.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2-hidroksi-1-okso-2-fenil-propil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(1 H-indol-2-ilkarbonil)-1 H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(1H-indol-3-ilkarbonil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(1H-indol-5-ilkarbonil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(1-metil-1H-indol-2-il)karbonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-benzofuranilkarbonil)-1 H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-piridinilkarbonil)-1 H-1,4-benzodiazepīna N-oksīda dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2-piridinilkarbonil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-iimetil)-7-fenil-4-(2-hinolinilkarbonil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(1-izčhinolinilkarbonil)-1H- 1.4- benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(3-hlor-2-nitrobenzoil)-1H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-nitrobenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(3-metoksi-2-nitrobenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(1 H-indol-4-ilkarbonil)-1 H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(2,6-dihidroksi-3-naftoil)-1 H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(1 H-benzimidazol-5-ilkarbo-nil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-{1H-benzotriazol-5-ilkarbo-nil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(4-metoksi-2-hinolinil)-karbonil]-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; N-^-tP.SAS-tetrahidro-l-O H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepin-4-il]karbonil}fenil)acetamīda dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2-metil-1-okso-2-fenil-propil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2-dimetilaminobenzoil)-1H- 1.4- benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-etoksibenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 12 4-[2-hidroksi-(1 .l’-bifeniO-S-ilkarbonin-Ž.S^.S-tetrahidro-l^l H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepTna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-{2-[(2-hidroksietil)tio]-benzoil}-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-metoksi-1 -naftoil)-1 H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(4-hidroksi-2-hinolinil)-karbonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2-{[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepin-4-il]karbonil}benzamīda dihidrogēnhlorīds; N-(1,1-dimetiletil)-2-{[2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-1H-1,4-benzodiazepin-4-il]karbonil}benzamīda dihidrogēnhlorīds; N-(4-fluorfenil)-N’-(3-{[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepin-4-il]karbonil}fenil)urīnvielas dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(3-metil-4-okso-2-fenil-4H-benzopiran-8-il)karbonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(3-trifluormetoksibenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-ciānbenzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(2-{[(4-metilfenil)sulfonil]-amino}benzoil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(6-hinolinilkarbonil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-{8-hinolinilkarbonil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(benzo[b]tiofen-2-ilkarbonil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-<4-dimetilamino-1 -naftoil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-{1 H-purin-6-ilkarbonil)-1 H- 1.4- benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(4-metoksifenilacetil)-1 H- 1.4- benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(5-metil-1-fenil-1H-pirazol-4-il)karbonilļ-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-iImetil)-7-fenil-4-[2-(2-metilfenil)-1-okso-propiI]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(4-fenil-2H-tetrahidropiran-4-il)karbonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[2-(metilfenilamino)benzoil]-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(4-hinolinilkarbonil)-1 H-1,4-benzodiazepīna N-oksīda dihidrogēnhlorīds; N-metil-N-(2-piridinilmetil)-2-{[2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepin-4-il]karbonil}benzamīda trihidrogēnhlorīds; 13 LV 12150 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(3-izohinolinilkarbonil)-1H- 1.4- benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-[(3-naftiltio)acetil]-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-[(1,1 ’-bifenil)-4-ilacetil]-1 H- 1.4- benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(2-naftililacetil)-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilrnetil)-7-fenil-4-[(1,1’-bifenil)-2-karbonil]-1H- 1.4- benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(2-fenil-4-hinolinil)karbonil]-1 H-1,4-benzodiazepīna trifluoracetāts (1:3); 2.3.4.5- tetrah id ro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-piridinilacetil)-1 H-1,4-benzodiazepīna trifluoracetāts (1:3); 2.3.4.5- tetrahidro-1-(1H-imidazol-4-iJmetil)-7-fenil-4-(9H-fluoren-9-ilacetil)-1H- 1.4- benzodiazepīna trifluoracetāts (1:2); (S)-4-(2-dimetilamino-1-okso-3-fenilpropil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna trifluoracetāts (1:3); (S)-4-[(2-okso-4-fenil-3-oksazolidinil)acetil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna trifluoracetāts (1:3); 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(9-akridinilkarbonil)-1 H-1,4-benzodiazepīna trifluoracetāts (1:3); 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(3-fenoksibenzoil)-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-[(4’-trifluomnetil-1,1 ’-bifenil)-2-karbonil]-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(4-fenoksibenzoil)-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1 H-imidazo(-4-ilmetil)-7-fenil-4-(2-naftoil)-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(1-okso-4-fenilbutil)-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(2-fenoksifenil)acetil]-1H- 1.4- benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-{2-[(4-metilfenil)sulfinil]-benzoil}-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-{2-[(fenilmetil)aminoļbenzoil}-1 H-1,4-benzodiazepīna trifluoracetāts (1:3); 1.2.3.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-N,N-difenil-4H-1,4-benzodiazepīn-4-karboksamīda hidrogēnhlorīds; 1.2.3.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-a,7-difenil-4H-1,4-benzodiazepīn-4-etiķskābes metilestera hidrogēnhlorīds; 4-acetil-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenil-metil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 14 (R)-4-acetil-2,3,4,5-tetrahidro-1-(1H-imidazoi-4-ilmetil)-3-fenilmetil-7-fenil-1H-1,4-benzodiazepīna hidrogēnhlorīds; 7- brom-4-[(2-dimetilaminoetil)sulfonil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1H-1,4-benzodiazepTna trifluoracetāts (1:2); 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[(1,2,3,4-tetrahidro-1-hinolinil)karbonil]-1 H-1,4-benzodiazepTna hidrogēnhlorīds; N-etil-1,2,3,5-tetrah id ro-1 -(1 H-imidazol-4-ilmetil)-N,7-difenil-4H-1,4-benzo-diazepīn-4-karboksamīda hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilrnetil)-7-fenil-4-[(2,3-dihidro-1H-indol-4-il)karbonil]-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-3-fenilmetil-7-(4-piri-dinil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; (R)-4-[(2-dimetilaminoetil)sulfonil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-7-fenil-1 H-1,4-benzodiazepīna trifluoracetāts (1:1); [2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-(1 -naftoil)-1 H-1,4-benzodiazepin- 8- il]karbamīskābes cikloheksilestera dihidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1 -(1 -metil-1 H-imidazol-5-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1-metil-1H-imidazol-5-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-fenil-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-pirido[3,2-e]-1,4-diazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[1,2-dioksoetil-2-(4-hlor-fenil)]-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4-(1,2-dioksopropil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[1,2-dioksoetil-2-(4-nitro-fenil)]-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-[1,2-dioksoetil-2-(4-metoksi-fenil)]-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-7-fenil-4-(1,2-diokso-3,3,3-trifluor-propil)-1 H-1,4-benzodiazepīna trifluoracetāts (1:2); (R)-7-hlor-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-pirido[3,2-e]-1,4-diazepīna hidrogēnhlorīds; 6,7,8,9-tetrahidro-5-(1H-imidazol-4-ilmetil)-8-(1-naftoil)-2-fenil-5H-pirimido-[5,4-e][1,4]diazepīna hidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilacetil)-3-fenil-metil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-iletil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 8-cikloheksilkarbonilamino-1,2,3,5-tetrahidro-1-(1H-i’midazol-4-ilmetii)-3-fenii-metil-4H-1,4-benzodiazepīn-4-karbonskābes metilestera dihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzo-diazepin-8-il]-1 -piperidīnkarboksamīda dihidrogēnhlorīds; (R)-7-ciān-1,2,3,5-tetrahidro-1-(1 H-imidazol-4-iImetil)-3-fenilmetil-4H-1,4-benzo-diazepīn-4-karbonskābes etilestera hidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-4-metilsulfonil-1 H-1,4-benzodiazepin-8-il]cikloheksānkarboksamīda dihidrogēnhlorīds; 15 LV 12150 (R)-7-ciān-4-[(2-dimetilaminoetil)sulfonil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepTna dihidrogēnhlorīds; (R)-7-ciān-4-{[2-(4-morfolinil)etil]sulfonil}-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-(2-metoksi-3-metilbenzoil)-1 H- 1.4- benzodiazepin-8-il]cikloheksānkarboksamīda dihidrogēnhlorīds; 8-cikloheksilkarbonilamino-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-N-fenil-1 H-1,4-benzodiazepīn-karboksamīda dihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-[(2-metilfenil)sulfonil]-1 H-1,4-benzodiazepin-8-il]cikloheksānkarboksamīda dihidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-[(2-metoksifenil)karbonil]-1 H- 1.4- benzodiazepin-8-il]cikloheksānkarboksamīda dihidrogēnhlorīds; (R)-7-ciān-1 ,2,3,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetii-4H-1,4-benzo-diazepīn-4-sulfonskābes etilestera hidrogēnhlorīds; (3R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-[ciān-(1H-imidazol-4-il)metil]-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (3R)-1 -[2-amino-1 -(1 H-imidazoM-iOetil^.S^.S-tetrahidro^-metilsulfonil-S-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (3R)-1-[2-dimetilamino-1-(1H-imidazol-4-il)etil]-2,3,4,5-tetrahidro-4-metilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (3R)-1-[2-amino-1-(1H-imidazol-4-il)etil]-2,3,4,5-tetrahidro-4-metilsulfonil-3-fenilmetil-7-brom-1H-1,4-benzodiazepīna dihidrogēnhlorīds; (3R)-1-[2-dimetilamino-1-(1H-imidazol-4-il)etil]-2,3,4,5-tetrahidro-4-metilsulfonil- 3- fenilmetil-7-brom-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-ciān-1,3,4)5-tetrahidro-1-(1-metil-1H-imidazol-5-ilmetil)-3-fenilmetil-4-fenil-sulfonil-2H-1,4-benzodiazepin-2-ona hidrogēnhlorīds; 7-ciān-1,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-fenilsulfonil-2H- 1.4- benzodiazepin-2-ona hidrogēnhlorīds; 7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(2-feniletil)-4-metilsulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3[(3-hlorfenil)metil]-4-metil-sulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R) -7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-cikloheksilmetil-4-metil-sulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3[(2-hlorfenil)metil]-4-metil-sulfonil-1H-1,4-benzodiazepīna dihidrogēnhlorīds; (S) -7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-cikloheksilmetil-4-metil-sulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3[(4-metoksifenil)metil]-4-metilsulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 4- acetil-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-iimetil)-3[(2-hlorfenil)metil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 4-acetil-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3[(3-hlorfenil)metil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-brom-2,3,4,5-tetrahidro-1-{1H-imidazol-4-ilmetil)-3[(4-hidroksifenil)metil]-4-metilsulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-3-(3-piridinilmetil)-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 16 2.3.4.5- tetra h īd ro-8-h id ro ksi metil-1 -(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepTna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-8-fenoksimetil-1-{1H-imidazol-4-ilmetil)-4-(1-naftoil)-1H-1,4-benzodiazepīna dihidrogēnhlorīds; N-cikloheksil-2,3,4,5-tetrahidro-1-{1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīn-8-karboksamīda dihidrogēnhlorīds; N-cikloheksilmetil-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-iimetil)-4-(1 -naftoil)-1 H- 1.4- benzodiazepīn-8-karboksamīda dihidrogēnhlorīds; N-fenilmetil-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-(1-naftoil)-1 H-1,4-benzodiazepīn-8-karboksamīda dihidrogēnhlorīds; (R)-4-acetil-7-[2-(dimetilaminometil)fenil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-4-acetil-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1H- 1.4- benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-(1-okso-butil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-3-fenilmetil-4-(2-metil-1-oksopropil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3l4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-(2-piridinil-acetil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-(2-tienil-sulfonil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-3-fenilmetil-4-[(1 -metiletil)-sulfonil]-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-trifluormetil-sulfonil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-propilsulfo-nil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-fenilsulfo-nil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-fenil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-fenilsulfonil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-fenil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-3-fenilmetil-4-propilsulfo-nil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-[(4-fluor-fenil)sulfonil]-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetit)-3-fenilmetil-4-[(3-ciān-fenil)sulfonil]-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-[(1-metil-1H-imidazoi-2-il)sulfonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-[(3-brom-fenil)sulfonil]-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-N-(5-{[7-ciān-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepin-4-ilļsulfonil}-4-metil-2-tiazolil)acetamīda dihidrogēnhlorīds; 4-acetil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-7-(4-piridinil)-1H- 1.4- benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazoi-4-ilmeti!)-4-(2-fenil-2,2-dioksoetil)-7-(4-piridin-il)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 17 LV 12150 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-trifluormetoksibenzoil)-7-(4-piri-dinil)-1 H-1,4-benzodiazepTna trihidrogēnhlorīds; (R)-7-fenil-2,3,4,5-tetrahidro-1-{1-metil-1H-imidazol-5-ilrnetil)-3-fenilmetil-4-metilsulfonil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-fenilacetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 4-(2-benzotiazolil)-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetii-7-(3-piridinil)-4-trifluor-acetil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-7-(3-piridinil)-4-metil-sulfonil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 7-brom-3-[(1,1-dimetiletoksi)metil]-1,2,3,4-tetrahidro-1-(1 H-imidazol-4-ilmetil)-5H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenoksimetil-7-brom-4-metilsulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-3-oksimetil-7-brom-4-metilsulfonil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 7-brom-3-[(1,1-dimetiletoksi)metil]-1,2,3,4-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-metilsulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; [7-brom-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzo-diazepin-8-il]karbamīnskābes 2-metilpropilesteris; N-[4-acetil-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzo-diazepi-8-ii]cikloheksānkarbonamīda dihidrogēnhlorīds; [7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepin-8-il]karbamīnskābes 2-metilpropilesteris; (R)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonil-3-fenilmetil-7-ciān-1 H-1,4-benzodiazepīna hidrogēnhlorīds 2.3.4.5- tetrahidro-1 -(1 H-imidazol-4-ilmetil)-3-fenilmetil-7-brom-1 H-1,4-benzo-diazepīn-4-acetamīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-dimetilaminoacetil-7-brom-1 H-1,4-benzodiazepīns; (R)-7-brom-4-(1,2-dioksopropil)-2)3I4,5-tetrahidro-1-(1H-imidazol-4-iimetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts; (R)-7-brom-4-ciklopropilkarbonil-2,3I4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts; (R)-7-brom-4-propilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenil-metil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 7-brom-2,3,4,5-1,4-bis(1 H-imidazol-4-i!metil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-brom-1,2,3,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-N,N-dimetil-3-fenilmetil-4H-1,4-benzodiazepīn-4-sulfonamīda hidrogēnhlorīds; 7-ciān-4-propilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-1,2,3,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-N,N-dimetil-3-feniImetil-4H-1,4-benzodiazepīn-4-karboksamīda hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1H-imidazol-4-ilrnetil)-NlN-dietil-3-fenilrnetil-4-metilsulfonil-1 H-1,4-benzodiazepīn-7-karboksamīda hidrogēnhlorīds; 18 2,3,4,5-tetrah id ro-1 -(1 H-imidazol-4-ilmetil)-7-fenil-4-(1-fenil-1 H-tetrazol-5-il)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-(2-pirazinil-karbonii)-4H-1,4-benzodiazepTna hidrogēnhlorīds; (R)-4-[7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4H-1,4-benzodiazepin-4-il]-4-oksobutānskābes metilestera hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1(1H-imidazol-4-ilmetil)-4-(4-morfolinilkarbonil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R) -7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-{[2-(1-piroli-dinil)etil]sulfonil}-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (S) -2,3,4,5-tetrah!dro-1-(1H-imidazol-4-ilmetil)-4-metiIsulfonil-3-{3-piridinilmetil)-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-fenil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(3-piridinilmetil)-4-(2-tienilsulfonil)-1H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-fenil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(3-piridinilmetil)-4-propil-sulfonil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(2-piridinilmetil)-4-metilsulfonil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 7-(2-pirimidinil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(2-piridinilmetil)-4-metilsulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-3-fenilmetil-4-trifiuor-metilsulfonil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-fenil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-trifluoracetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-(4-piridinil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-metil-sulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-(4-piridinil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-(2-tienilsulfonil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-(4-piridinil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-fenil-sulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-(4-piridinil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-propil-sulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-[(3,5-dimetil-izoksazol-4-il)sulfonil]-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-feniimetil-4-[(4-ciān-fenil)sulfonilj-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-(2,2,2-trifluoretilsulfonil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetii-4-(2,2,2-trifluoretilsulfonil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-4-[(5-brom-2-tienil)sulfonil]-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-il-metil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-feniImetil-4-(4-metoksi-fenilsulfonil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; N-{[7-brom-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-metiIsulfonil-1 H-1,4-benzodiazepin-3-il]metil}benzamīda dihidrogēnhlorīds; (R)-7-ciān-1,2,3,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-N,N-dimetil-3-fenilmetil-4H-1,4-benzodiazepīn-4-sulfonamīda hidrogēnhlorīds; 19 LV 12150 (R)-7-ciān-1,2,3,5-tetrahidro-1-(1-metil-1H-imidazol-5-ilmetil)-N,N-dimetil-3-fenilmetil-4H-1,4-benzodiazepīn-4-sulfonamīda hidrogēnhlorTds; (R)-7-hlor-2,3,4,5-tetrahidro-1 -(1 -metil-1 H-imidazol-5-ilmetil)-3-fenilmetii-4-metilsulfonii-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-hlor-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-metilsulfonil-1 H-1,4-benzodiazepīna hidrogēnhlorTds; (R)-7-hlor-2,3,4,5-tetrahidro-1-(1-metil-1 H-imidazol-5-ilmetil)-3-fenilmetil-4-fenilsulfonil-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(piridin3-ilmetil)-4-metilsulfonil-1 H-1,4-benzodiazepTna tetrahidrogēnhlorīds; (R)-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-2-ilmetil)-3-fenilmetil-4-metil-sulfonil-1 H-1,4-benzodiazepTna dihidrogēnhlorTds; (R)-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-[(1-metil-1 H-imidazol-4-il)sulfonil]-1 H-1,4-benzodiazepTna trihidrogēnhlorTds; (R)-7-hlor-2,3,4,5-tetrahydro-1-(1-metilimidazol-5-ilmetil)-4-[(2-morfolin-4-iletil)-sulfonil]-3-fenilmetil-1 H-1,4-benzodiazepTna dihidrogēnhlorTds; (R)-7-hlor-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ilmetil)-4-[(2-morfolin-4-iletil)-sulfonil]-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorTds; (R)-7-hlor-4-dimetilaminosulfonil-1-(1-metil-1 H-imidazol-5-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-hlor-2,3,4,5-tetrahydro-1-(1-metilimidazol-5-ilmetil)-4-[(4-metilpiperidin-4-iietil)sulfonilj-3-fenilmetil-1 H-1,4-benzodiazepTna dihidrogēnhlorTds; (R)-7-brom-2,3,4,5-tetrahydro-1-(1-metilimidazol-5-ilmetil)-4-[(4-metilpiperidin-4-iletil)sulfonil]-3-fenilmetil-1 H-1,4-benzodiazepTna dihidrogēnhlorTds; (R)-7-ciān-1,2,3,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-4H-1,4-benzo-diazepm-4-karbonskābes 2-metiletilestera hidrogēnhlorTds; (R)-7-brom-2,3,4,5-tetrahidro-4-{[2-(1 H-imidazol-1 -il)etil]sulfonil}-1 -(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-propilsulfonil-3-(3-piri-dinilmetil)-1 H-1,4-benzodiazepTna hidrogēnhlorTds; 7-brom-2,3,4,5-tetrahydro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzo-diazepin-5-ona hidrogēnhlorTds; (R)-7-brom-2,3,4,5-tetrahydro-1 -(1 H-imidazol-1 -ilacetil)-4-metilsulfonil-3-fenil-metil-1 H-1,4-benzodiazepTna trifluoracetāts; 1.2.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-2-(2-feniletil)-3H-1,4-benzodiazepin- 3- ons; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-ilmetil)-4-metilsulfonil-2-(2-feniletil)-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-7-fenil-3-(4-piridin-ilmetil)-1 H-1,4-benzodiazepTna dihidrogēnhlorTds; (R)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonil-7-ciān-3-(4-piridin-ilmetil)-1H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-ciān-1,2,3,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-N,N-dimetil-3-(3-piridinil-metil)-4H-1,4-benzodiazepīn-4-karboksamīda dihidrogēnhlorTds; (R)-7-ciān-1,2,3,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-N,N-dimetil-3-(3-piridinil-metil)-4H-1,4-benzodiazepTn-4-sulfonamTda dihidrogēnhlorTds; 4- (4-fluorfenilsulfonil)-2,3,4,5-tetrahidro-1-[(1-metii-1H-imidazol-5-il)-3-fenilmetil-1H-tieno[2,3-e]-1,4-diazepīna hidrogēnhlorTds; 20 (R)-2,3,4,5-tetrahidro-1 -[1-(4-ciānfenilmetif)-imidazol-5-iImetil]-4-metilsulfonil-3-fenilmetil-7-ciān-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R^.SAS-tetrahidro-HI-A-ciānfenilrnetilHmidazoM-ilmetillA-metilsulfonil-S-fenilmetil-7-ciān-1 H-1,4-benzodiazepTna hidrogēnhlorīds; (R)A-benzoil-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazolA-ilmetil)-3-fenilmetil-1H- 1.4- benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3A5-tetrahidro-1-(1-metil-1 H-imidazol-5-ilmetil)-3-(piridin-3-ilmetil)-4-metilsulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1 -metil-1 H-imidazol-5-ilmetil)-3-(piridin-3-ilmetil)-4-propilsulfonil-1H-1,4-benzodiazepīna trihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(piridin-3-ilmetil)-4-fenil-sulfonil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 7-fenil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-metilsulfonil-1H- 1.4- benzodiazepīns; 1,2,3,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-N-(1-naftil)-7-fenil-4H-1,4-benzo-diazepīn-4-karboksamīda hidrogēnhlorīds; (S^-brom^.SAS-tetrahidro-l-OH-imidazolA-ilmetiO-S-fenilmetilA-metilsuIfo-nil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; N-[2,3,4,5-tetrahidro-1 -{1 H-imidazol-4-ilmetil)-4-(2,3-dimetilbenzoil)-1 H-1,4-benzodiazepin-8-il]cikloheksānkarboksamīds dihidrogēnhlorīds; (R)-7-ciān-N-(2-dimetilaminoetil)-2,3I4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-N-metil-3-fenilmetil-1 H-1,4-benzodiazepīnA-karboksamīda trifluoracetāts (1:2); 7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-2-okso-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts; (R)-7-ciān-4-(2-furanilkarbonil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts (1:1); (R)-7-ciān-4-(4-nitrofenilsulfonil)-2l3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts; (R)-7-ciān-4-{[(4-metil-1-piperazinil)fenil]sulfonil}-2,3,4,5-tetrahidro-1-(1H-imid-azol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts; (R)-7-ciān-4-[(4-dimetilaminofenil)sulfonil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-feniīmetil-1 H-1,4-benzodiazepīna trifluoracetāts; (R)-7-brom-4-[(2-dimetilaminoetil)sulfonil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-4-(3-piridinilsulfonil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds 4-metilsulfonil-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenil-metil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-fenil-4-[(3-dimetilaminopropil)sulfonil]-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; 4-butil-2,3,4,5-tetrahidro-1-{1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; (R)-7-brom-4-{[2-(4-morfolinil)etil]sulfonil}-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 21 LV 12150 (R)-7-brom-4-{[2-(4-morfolinil)etil]sulfonil}-2,3,4,5-tetrahidro-1-(1-metil-1H-imid-azol-5-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-4-(4-morfolinilsulfonil)-1 -(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-ciān-4-(4-aminofenilsulfonil)-1-(1-imidazol-4-ilmetil)-3-fenilmetil-1H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1 H-imidazol-4-iimetil)-4-[(4-piridiltio)acetiI]-7-fenil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; N-(4-hlorfeniI)-N’-ciān-1,2,3,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-7-fenil-4H-1,4-benzodiazepīn-4-imīdamīda hidrogēnhlorīds; 4-acetil-7-brom-1,2,4,5,1’,3’-heksahidro-1-(1H-imidazol-4-ilmetil)spiro[3H-1,4-benzodiazepīn-3,2’-[2H]indēna dihidrogēnhlorīds; 7-brom-4-(3-dimetilamono-1-oksopropil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna trifluoracetāts (1:1); (RJ^.S^^-tetrahidro-l-CI-metii-l H-imidazol-5-ilmetil)-4-fenilsulfoniI-3-fenilmetil-7-ciān-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 2.3.4.5- tetrahidro-1-(1-metil-1H-imidazol-5-ilmetil)-4-metilsulfonil-7-fenil-3-(piridin-3-ilmetil)-1 H-1,4-benzodiazepīna sālskābes (1:1,5) un trifluoretiķskābes (1:0,75) sāls; 4-(4-fluorfenilsulfonil)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-2-(2-feniletiI)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-2-(2-feniietil)-1H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-4-{[2-(4-morfolinil)etil]sulfonil}-2,3,4,5-tetrahidro-1-(1-metil-1H-imid-azol-5-ilmetil)-3-fenilmetil-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-3-(4-brom-fenil)metil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(tiazol-4-ilmetil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-brom-4-propilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(4-bromfenilmetil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(3-piridinilmetil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-(3-piridin-ilmetil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; (R)-7-brom-4-metilsulfonil-2,3,4,5-tetrahidro-1-(1H-imidazol-5-ilmetil)-(3-piridinil-metil)-1 H-1,4-benzodiazepīna dihidrogēnhlorīds; 1,2,3,4-tetrahidro-7-brom-4-(1H-imidazol-4-ilmetil)-3-fenilmetil-1-fenilmetiloksi-karbonilhinoksalīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil‘)-4-fenilsulfonil-3-(4-ciān-fenilmetil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-4-[(N-metil-N-fenilmetil)-aminosulfonil]-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[N-(tetrahidroizo-hinolinil)sulfonil]-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonil-3-(2-tienil-metil)-1 H-1,4-benzodiazepīna hidrogēnhlorīds; 22 cis-2,3,4,5-tetrah id ro-1,5-bis(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-1,5-benzo-diazepīn-2-karbonskābes etilestera trifluoracetāts (1:2); (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(N-piperidinil)sulfonil]-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-1-metilimidazol-5-ilmetil)-4-(2-tienilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-ciān-2,314I5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(2-dimetilaminoetil)-sulfonil]-3-(piridin-3-ilmetil)-1 H-1,4-benzodiazepīna trihidrogēnhlorīds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-1-metilimidazol-5-ilmetil)-4-propilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepTna hidrogēnhlorTds; N-ciān-N’-metil-7-fenil-1,2,3,5-tetrahidro-1-(1 H-imidazol-4-ilmetil)-4H-1,4-benzo-diazepm-4-imīdamTda hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-nitrofenilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(4-metilfenilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-butilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-trifluormetilfenil-sulfonil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-trifluormetoksifenil-sulfonil)-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-metoksikarbonilfenil-sulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(2-metilsulfonilfenil)-sulfonil]-3-fenilmetil-1 H-1,4-benzodiazepīna hidrogēnhlorTds; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(4-metilsulfonilfenil)-sulfonil]-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(4-trifluormetilfenil-sulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(3-metoksipropil-sulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(3,4-dimetoksifenil-sulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonil-3-(4-fluor-fenilmetil)-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(N-ciklopropilmetil-N-propil)sulfonil]-3-fenilmetil-1 H-1,4-benzodiazepīns; (R^-ciān^.S^.S-tetrahidro-l-ilH-imidazoM-ilmetilH-iN.N-dibutilamino-sulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metānsulfonil-3-fenil-metil-1 H-pirido[3,4-e]-1,4-diazepīns; 1,2,3,4-tetrahidro-7-brom-4(1 H-imidazol-4-ilmetil)-2-fenilmetil-1 -metilsulfonil-hinoksafīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(imidazol-4-iI)nnetilsulfo-n i l]-3-fe n i I meti I-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-propilsulfonil-3-(2-tienil-metil)-1 H-1,4-benzodiazepTns; 23 LV 12150 (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-tienilsulfonil)-3-(2-tienilmetil)-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(3-metiltiopropilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-4-(3-metiltioksopropil-sulfonil)-3-fenilmetīl-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(3-metilsulfonilpropil-sulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-metilpropilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-ciklopentilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilrnetil)-4-(4,4,4-trifluorbutilsulfo-nil)-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilmetilsulfonil-3-fenil-metil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-{[2-(5-benzoilamino-metil)tienil]sulfonil}-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-iimetil)-4-{2-[1-(3-hlor-5-metil-piridin-2-il)piroliljsulfonii}-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(4-karboksifenilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-{[(3-metii-1,2,4-oksa-diazol-5-il)fenil]sulfonil}-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2,5-dimetoksifenil-sulfonii)-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-[(N-tetrahidrohinolinil)-sulfoniI]-3-fenilmetii-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-{[N,N-bis(2-metilpropil)-amino]sulfonii}-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(N-metil-N-fenilamino-sulfonil)-3-feni!metil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsuifonil-3-[2-(2,6-dimetiifenil)etil]-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[1-(N-ftalimidoetil)imidazol-5-ilmetil)-4-metil-sulfonil-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-{[2-(N,N-dimetilamino)etil]innidazol-5-ilnnetil}-4-metilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[(2-aminoetil)imidazol-5-ilmetil]-4-metiisulfonil-3-fenilmetil-1 H-1,4-benzodiazepTns; (R)-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-iimetil)-4-metānsulfonil-3-[2-{2,6-dimetilfenil)etilļ-1 H-tieno[2,3-e]-1,4-diazepTns; (R)-7-brom-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-4-metānsuifonil-3-[2-(2,6-dimetilfenil)etil]-1 H-tieno[3,2-e]-1,4-diazepTns; (R)-4-metānsulfonil-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-3-fenilmetil-1 H-8-oksopirimidino[4,5-e]-1,4-diazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-4-fenilsulfonil-3-[4-(2-metoksietoksi)fenilmetii]-1 H-1,4-benzodiazepTns; 24 (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonil-3-[4-(2-dimetilaminoetoksi)fenilmetil]-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilsulfonii)-4-metilsulfonil-3-fenil-metil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilsulfonil)-4-propilsulfonil-3-fenil-metil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilsulfonil)-4-fenilsulfonil-3-fenil-metil-1 H-1,4-benzodiazepTns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilsulfonil)-4-(2-tienilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-metiisulfonil-3-(R)-((R)-1 -feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-propilsulfonil-3-(R)-((R)-1-feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-feniisulfonil-3-(R)-((R)-1-feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-tienilsulfonil)-3-(R)-((R)-1 -feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-metilsulfonil-3-(S)-((R)-1 -feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-propilsuifonil-3-(S)-((R)-1-feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonil-3-(S)-((R)-1-feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-tienilsulfonil)-3-(S)-((R)-1 feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2I3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-4-metilsulfoniI-3-(R)-((S)-1-feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-propilsuifonil-3-(R)-((S)-1 -feniietil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonil-3-(R)-((S)-1-feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-tienilsulfonil)-3-(R)-((S)-1 feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsuifonil-3-(S)-((S)-1-feniletil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-iimetil)-4-propilsulfonil-3-(S)-((S)-1-feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1 -(1 H-imidazol-4-ilmetil)-4-fenilsulfonil-3-(S)-((S)-1 -feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-tieniisulfonil)-3-(S)-((S)-1 feniletil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metiisulfonil-3-(R)-((R)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-propilsulfonil-3-(R)-((R)-fenilciklopropil)-1 H-1,4-benzodiazepTns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-4-feniisulfonii-3-(R)-((R)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 25 LV 12150 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-tienilsulfonil)-3-(R)-((R)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-3-(S)-((R)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,314,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-propilsulfonil-3-(S)-((R)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-iimetil)-4-fenilsulfonil-3-(S)-((R)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-(2-tienilsulfonii)-3-(S)-((R)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-metilsulfonil-3-(R)-((S)-feniiciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-propilsulfonil-3-(R)-((S)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonii-3-(R)-((S)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-4-(2-tieniisulfonii)-3-(R)-((S)-fenilciklopropil)-1 H-1,4-benzodiazepīns; ī-ciān^.S^.S-tetrahidro-l-ilH-imidazoM-ilmetilJ^-metilsulfonil-S-iSJ-iiS)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-i!metil)-4-propilsulfonil-3-(S)-((S)-fenilciklopropii)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-4-fenilsulfonil-3-(S)-((S)-fenilciklopropil)-1 H-1,4-benzodiazepīns; 7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazoi-4-ilmetil)-4-(2-tienilsulfonil)-3-(S)-((S)-fenilciklopropil)-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmeti!)-4-{2-[5-(piridin-2-il)tienil]-sulfonil}-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[3-(1H-imidazol-2-il)propil]-4-fenilsulfonil-3-fenil-metil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[3-(1H-imidazol-2-il)propil]-4-metilsulfonil-3-fenil-metil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[3-(1H-imidazol-2-il)propil]-4-propilsulfonil-3-fenil-metil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[3-(1H-imidazol-2-il)propii]-4-(2-tienilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[2-(1H-imidazol-2-il)etilsulfonii]-4-fenilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[2-(1H-imidazol-2-il)etilsulfoniI]-4-metilsulfonil-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[2-(1H-imidazoi-2-il)etilsulfonil]-4-propiisulfonil-3-fenilmetii-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-[2-(1H-imidazol-2-il)etilsulfonil]-4-(2-tienilsulfonil)-3-fenilmetil-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-feniimetil-4-[(1-oksoetil)-amino]-1 H-1,4-benzodiazepīns; (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-fenilmetil-4-metān-sulfoniIamino-1 H-1,4-benzodiazepīns; 26 (R)-7-ciān-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetii)-3-fenilmetil-4-fenilsulfonil-amino-1 H-1,4-benzodiazepTns.
8. Savienojuma pēc 1. punkta pielietojums zīdītāju farnezilproteīntrans-ferāzes inhibēšanai.
9. Savienojuma pēc 1. punkta pielietojums zīdītāju prenilproteīntrans-ferāzes inhibēšanai.
10. Savienojuma pēc 1. punkta pielietojums zīdītāju audzēju nomākšanai.
11. Savienojuma pēc 1. punkta pielietojums tādu zīdītāju slimību ārstēšanai, kurās iesaistīta signālu nodošana ar Ras starpniecību.
12. Savienojuma pēc 1. punkta pielietojums tādu zīdītāju slimību ārstēšanai, kurās iesaistīti proteīni, kas pēc translācijas tiek modificēti ar farnezilproteīntransferāzi.
13. Savienojuma pēc 1. punkta pielietojums tādu zīdītāju slimību ārstēšanai, kurās iesaistīti proteīni, kas pēc translācijas tiek modificēti ar geranilgeranilproteīntransferāzi.
14. Savienojums ar formulu
kurā Ri ir ņemts no rindas: Cl, Br, fenilgrupa, piridilgrupa un ciāngrupa; R2 ir aralkilgrupa vai heterociklilalkilgrupa.
15. Savienojums ar formulu
H kurā Ri ir ņemts no rindas: Cl, Br, fenilgrupa, piridilgrupa un ciāngrupa; R2 ir aralkilgrupa vai heterociklilalkilgrupa. 27 LV 12150
16. Savienojums ar formulu
kurā Rļ ņemts no rindas: Cl, Br, fenilgrupa, piridilgrupa un ciāngrupa; R2 ir aralkilgrupa vai heterociklilalkiigrupa; R3 ir ņemts no rindas: aizvietota alkilgrupa, aizvietota arilgrupa un aizvietota heterocikliska grupa; Z1 ir ņemts no rindsa CO, S02, C02, CONHR5l S03, S02NR5i C(NCN)NR5; R5 ņemts no rindas: ūdeņraža atoms, zemākā alkilgrupa, aizvietota alkilgrupa, arilgrupa, aizvietota arilgrupa.
17. Savienojums ar formulu
I Prot kurā Rļ ņemts no rindas: Cl, Br, fenilgrupa, piridilgrupa un ciāngrupa; R2 ir aralkilgrupa vai heterociklilalkiigrupa; R3 ir ņemts no rindas: aizvietota alkilgrupa, aizvietota arilgrupa un aizvietota heterocikliska grupa; Z1 ir ņemts no rindsa CO, S02, C02, CONHR5, S03, S02NR5, C(NCN)NR5; R5 ņemts no rindas: ūdeņraža atoms, zemākā alkilgrupa, aizvietota alkilgrupa, arilgrupa, aizvietota arilgrupa, Prot ir trifenilmetilgrupa vai Boc-grupa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1226596P | 1996-02-26 | 1996-02-26 | |
US2280596P | 1996-07-25 | 1996-07-25 | |
PCT/US1997/002920 WO1997030992A1 (en) | 1996-02-26 | 1997-02-24 | Inhibitors of farnesyl protein transferase |
Publications (2)
Publication Number | Publication Date |
---|---|
LV12150A LV12150A (lv) | 1998-10-20 |
LV12150B true LV12150B (lv) | 1998-12-20 |
Family
ID=26683350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-98-129A LV12150B (lv) | 1996-02-26 | 1998-06-04 | Farneziltransferāzes inhibitori |
Country Status (24)
Country | Link |
---|---|
US (2) | US6011029A (lv) |
EP (2) | EP1481975A1 (lv) |
JP (1) | JP4115529B2 (lv) |
KR (1) | KR100522983B1 (lv) |
CN (2) | CN100376569C (lv) |
AU (1) | AU718676B2 (lv) |
BG (1) | BG64951B1 (lv) |
BR (1) | BR9707614A (lv) |
CA (1) | CA2239187C (lv) |
CZ (1) | CZ299762B6 (lv) |
EE (1) | EE04309B1 (lv) |
GE (1) | GEP20022616B (lv) |
HU (1) | HUP9902016A3 (lv) |
IL (2) | IL141908A (lv) |
LV (1) | LV12150B (lv) |
NO (1) | NO319395B1 (lv) |
NZ (1) | NZ330287A (lv) |
PL (1) | PL191502B1 (lv) |
RO (1) | RO121118B1 (lv) |
RU (1) | RU2225405C2 (lv) |
SK (1) | SK286568B6 (lv) |
TW (1) | TW496863B (lv) |
UA (1) | UA52642C2 (lv) |
WO (1) | WO1997030992A1 (lv) |
Families Citing this family (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117641A (en) | 1996-04-11 | 2000-09-12 | Mitotix, Inc. | Assays and reagents for identifying anti-fungal agents and uses related thereto |
JP2001513622A (ja) | 1996-04-11 | 2001-09-04 | マイトティックス インコーポレーテッド | 抗菌剤の同定のためのアッセイおよび試薬、並びにそれらに関連する利用 |
US6727082B1 (en) | 1996-04-11 | 2004-04-27 | Gpc Biotech Inc. | Assays and reagents for identifying anti-fungal agents, and uses related thereto |
JP2000514456A (ja) * | 1996-07-15 | 2000-10-31 | ブリストル―マイヤーズ・スクイブ・カンパニー | ファルネシルプロテイントランスフェラーゼのチアジオキソベンゾジアゼピン阻害剤 |
EP1019529A4 (en) * | 1997-08-27 | 2002-09-11 | Merck & Co Inc | METHOD FOR TREATING CANCER |
WO1999018951A1 (en) * | 1997-09-29 | 1999-04-22 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US6458783B1 (en) * | 1997-09-29 | 2002-10-01 | Bristol-Myers Squibb Company | Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase |
TR200002616T2 (tr) * | 1997-12-22 | 2000-11-21 | Bayer Corporation | Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi |
US6071903A (en) * | 1998-01-27 | 2000-06-06 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids |
US6423519B1 (en) | 1998-07-15 | 2002-07-23 | Gpc Biotech Inc. | Compositions and methods for inhibiting fungal growth |
AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU2477400A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Corporation | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
KR100708360B1 (ko) * | 1999-01-21 | 2007-04-17 | 브리스톨-마이어스스퀴브컴파니 | 라스-파르네실트란스퍼라제 억제제와술포부틸에테르-7-β-시클로덱스트린 또는2-히드록시프로필-β-시클로덱스트린과의 착물 및 방법 |
EP1158982A4 (en) * | 1999-03-03 | 2002-06-12 | Merck & Co Inc | Prenyl protein transferase inhibitors |
PT1169038E (pt) | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Inibidores cíclicos da proteína tirosina cinase |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
WO2000078303A1 (en) * | 1999-06-18 | 2000-12-28 | Thyreos Corporation | Non-malignant disease treatment with ras antagonists |
US20020115696A1 (en) | 1999-06-18 | 2002-08-22 | Yoel Kloog | Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists |
AU5667900A (en) | 1999-06-30 | 2001-01-22 | Prescient Neuropharma Inc. | 2-aminoindane analogs |
FR2796943A1 (fr) * | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique |
EP1088821A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
US6100395A (en) * | 2000-01-10 | 2000-08-08 | Bristol-Myers Squibb Company | Reductive alkylation of secondary amines with hydrosilane |
US6838467B2 (en) | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
AU2001246844A1 (en) * | 2000-04-07 | 2001-10-23 | Takeda Chemical Industries Ltd. | Soluble beta amyloid precursor protein secretion promoters |
ES2328225T3 (es) * | 2000-11-21 | 2009-11-11 | Janssen Pharmaceutica Nv | Derivados benzoheterociclicos inhibidores de la farnesil-transferasa. |
DK1339407T3 (da) * | 2000-11-28 | 2006-08-14 | Janssen Pharmaceutica Nv | Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom |
DE60119383T2 (de) * | 2000-12-27 | 2007-04-19 | Janssen Pharmaceutica N.V. | Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate |
ATE319704T1 (de) * | 2000-12-27 | 2006-03-15 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate |
WO2002056884A2 (en) * | 2001-01-22 | 2002-07-25 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
EP1353668B1 (en) | 2001-01-25 | 2008-03-19 | Bristol-Myers Squibb Company | Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer |
US7759323B2 (en) | 2001-05-22 | 2010-07-20 | Eisai R & D Management Co., Ltd. | Highly purified antiendotoxin compound |
EP1288713A1 (en) * | 2001-08-29 | 2003-03-05 | Chugai Photo Chemical Co. Ltd. | Processing agent for silver halide color photosensitive material and processing method thereof |
US20030134846A1 (en) * | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
EP1443936A4 (en) * | 2001-11-13 | 2006-01-11 | Bristol Myers Squibb Co | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUE-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS |
DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
WO2003068746A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
ATE366045T1 (de) * | 2002-03-15 | 2007-07-15 | Ciba Sc Holding Ag | Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen |
US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
CN1675154A (zh) * | 2002-06-07 | 2005-09-28 | 科蒂科股份有限公司 | 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物 |
WO2003106628A2 (en) * | 2002-06-17 | 2003-12-24 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase |
AU2003259717A1 (en) * | 2002-08-07 | 2004-02-25 | Bristol-Myers Squibb Company | Modulators of rabggt and methods of use thereof |
US7632858B2 (en) * | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
JP2004346059A (ja) * | 2003-01-28 | 2004-12-09 | Takeda Chem Ind Ltd | 受容体作動薬 |
CA2514547A1 (en) * | 2003-01-28 | 2004-08-12 | Takeda Pharmaceutical Company Limited | Receptor agonists |
US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
ES2297490T3 (es) | 2003-07-23 | 2008-05-01 | Bayer Pharmaceuticals Corporation | Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones. |
EP1656156A2 (en) | 2003-08-13 | 2006-05-17 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
US20050069553A1 (en) | 2003-08-13 | 2005-03-31 | Yi Zheng | Chimeric peptides for the regulation of GTPases |
US7256208B2 (en) * | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
CA2546727C (en) | 2003-11-20 | 2012-10-02 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7388027B2 (en) * | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7696241B2 (en) * | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20050272068A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | UCH-L1 expression and cancer therapy |
EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | TREATMENT OF SYNUCLEINOPATHIES |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
US20050288298A1 (en) * | 2004-03-18 | 2005-12-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US7323455B2 (en) * | 2004-03-24 | 2008-01-29 | Wyeth | 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
DK1815247T3 (da) | 2004-11-05 | 2013-03-11 | Janssen Pharmaceutica Nv | Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitet |
KR20070084325A (ko) | 2004-11-18 | 2007-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법 |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
CA2602351A1 (en) * | 2005-03-25 | 2006-10-05 | Kissei Pharmaceutical Co., Ltd. | Urea derivative, medicinal composition containing the same, and medicinal use of these |
US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
EP1879881A2 (en) * | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
AU2006257919A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
CA2617056A1 (en) | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
US7700592B2 (en) * | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
CN101374830A (zh) * | 2005-08-25 | 2009-02-25 | 先灵公司 | α2C肾上腺素受体激动剂 |
EA014370B1 (ru) | 2005-09-16 | 2010-10-29 | Янссен Фармацевтика Н.В. | Циклопропиламины в качестве модуляторов рецептора гистамина н |
EP1955073A2 (en) * | 2005-11-15 | 2008-08-13 | Brystol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof |
DE602007008837D1 (de) * | 2006-02-14 | 2010-10-14 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine |
KR101367645B1 (ko) | 2006-04-20 | 2014-02-27 | 얀센 파마슈티카 엔.브이. | C-fms 키나제의 저해제로서의 복소환식 화합물 |
US8859602B2 (en) | 2006-04-20 | 2014-10-14 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
RU2009125599A (ru) | 2006-12-04 | 2011-01-20 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Композиции и способы лечения рака cpg-богатой днк и купредоксинами |
CA2880932A1 (en) | 2006-12-14 | 2008-06-26 | Janssen Pharmaceutica N.V. | Process for the preparation of piperazinyl and diazepanyl benzamide derivatives |
WO2008089135A2 (en) * | 2007-01-12 | 2008-07-24 | University Of South Florida | Identification of biomarkers predictive of dasatinib effects in cancer cells |
KR20090114414A (ko) | 2007-02-08 | 2009-11-03 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 쿠프레독신으로 암을 예방하는 조성물과 방법 |
WO2008141081A1 (en) * | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2008144981A1 (fr) | 2007-05-25 | 2008-12-04 | Topharman Shanghai Co., Ltd. | Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine |
WO2008153858A1 (en) | 2007-06-05 | 2008-12-18 | Schering Corporation | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
WO2009105140A2 (en) | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
ES2637805T3 (es) * | 2008-05-05 | 2017-10-17 | Sanofi | Derivados de ácido ciclopentanocarboxílico fusionados sustituidos por acilamino y su uso como productos farmacéuticos |
WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
CA2743717A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
ES2425091T3 (es) * | 2009-05-26 | 2013-10-11 | Exelixis, Inc. | Benzoxazepinas como inhibidores de PI3K/mTOR y sus métodos de uso y fabricación |
EP2438059A1 (en) | 2009-06-05 | 2012-04-11 | Link Medicine Corporation | Aminopyrrolidinone derivatives and uses thereof |
DK2769737T3 (en) | 2009-07-20 | 2017-07-24 | Bristol Myers Squibb Co | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES |
WO2011041152A1 (en) | 2009-09-30 | 2011-04-07 | Schering Corporation | Novel compounds that are erk inhibitors |
AU2010322286B2 (en) | 2009-11-17 | 2014-06-05 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
EP2730561B1 (en) | 2010-04-06 | 2015-10-14 | Nippon Soda Co., Ltd. | Methods to prepare haloalkyl nitrogen-containing heterocyclic compounds |
AU2014201038B2 (en) * | 2010-04-06 | 2015-08-06 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and method for producing same |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
CN103442737B (zh) | 2011-01-20 | 2017-03-29 | 得克萨斯系统大学董事会 | Mri标记、递送和提取系统及其制造方法和用途 |
CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
KR102073445B1 (ko) | 2012-07-31 | 2020-02-04 | 다우 글로벌 테크놀로지스 엘엘씨 | 올레핀 중합 촉매 활성화제의 제조 방법 |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
ES2608628T3 (es) | 2012-08-07 | 2017-04-12 | Janssen Pharmaceutica Nv | Procedimiento para la preparacion de derivados de ester heterociclicos |
EP2924044B1 (en) | 2012-11-17 | 2018-10-31 | Beijing Shuobai Pharmaceutical Co., LTD | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
EP3401314B1 (en) * | 2013-03-15 | 2023-11-08 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
JP2017522016A (ja) | 2014-06-27 | 2017-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 培養哺乳動物輪部幹細胞、その産生方法及びその使用 |
WO2016164675A1 (en) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
CA2985123C (en) | 2015-08-17 | 2021-04-13 | Antonio Gualberto | Methods of treating cancer patients with farnesyltransferase inhibitors |
WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
JP7015059B2 (ja) | 2015-11-16 | 2022-02-15 | アラクセス ファーマ エルエルシー | 置換複素環式基を含む2-置換キナゾリン化合物およびその使用方法 |
WO2017184968A1 (en) | 2016-04-22 | 2017-10-26 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
CN109476641B (zh) * | 2016-05-24 | 2022-07-05 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
CN110312711A (zh) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
MY190861A (en) | 2016-11-03 | 2022-05-12 | Kura Oncology Inc | Farnesyltransferase inhibitors for use in methods of treating cancer |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
US9956215B1 (en) | 2017-02-21 | 2018-05-01 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
MX2019009821A (es) | 2017-02-21 | 2019-12-02 | Kura Oncology Inc | Metodos para tratar cancer con inhibidores de farnesiltransferasa. |
JP2020521742A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Krasの共有結合性阻害剤 |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
EP3630746A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
BR112020002591A2 (pt) | 2017-08-07 | 2020-07-28 | Kura Oncology, Inc. | método para o tratamento de câncer |
MA50250A (fr) | 2017-09-15 | 2020-07-22 | Forma Therapeutics Inc | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 |
WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
SG11202012767UA (en) | 2018-06-29 | 2021-01-28 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
UY38427A (es) | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
CN113286591A (zh) | 2018-11-01 | 2021-08-20 | 库拉肿瘤学公司 | 用法尼基转移酶抑制剂治疗癌症的方法 |
JP2022514654A (ja) | 2018-12-21 | 2022-02-14 | クラ オンコロジー, インコーポレイテッド | 扁平上皮癌のための治療法 |
US20220142983A1 (en) | 2019-03-01 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
WO2020190604A1 (en) | 2019-03-15 | 2020-09-24 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
TW202043487A (zh) | 2019-03-29 | 2020-12-01 | 美商庫拉腫瘤技術股份有限公司 | 以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法 |
US20220168296A1 (en) | 2019-04-01 | 2022-06-02 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
WO2020223583A1 (en) | 2019-05-02 | 2020-11-05 | Kura Oncology, Inc. | Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors |
WO2020236940A1 (en) * | 2019-05-20 | 2020-11-26 | California Institute Of Technology | Kras g12c inhibitors and uses thereof |
EP4142879A1 (en) | 2020-04-27 | 2023-03-08 | Novartis AG | Methods and compositions for ocular cell therapy |
US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
CN115745960B (zh) * | 2021-09-02 | 2024-08-30 | 中国科学院上海药物研究所 | 一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途 |
CN114230529A (zh) * | 2021-11-03 | 2022-03-25 | 河南大学 | 四氢喹喔啉磺酰胺衍生物及其制备方法与用途 |
WO2023143389A1 (zh) * | 2022-01-29 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | 稠杂环类化合物、其制备方法及其在医药上的应用 |
WO2024097606A1 (en) * | 2022-10-31 | 2024-05-10 | Eli Lilly And Company | Ahr agonists |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1923821A1 (de) * | 1969-05-09 | 1970-11-19 | Wuelfing J A Fa | 1,2,4,5-Tetrahydro-[3H]-benzo-1,4-diazepin-2,5-dion-Derivate,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten |
JPS6168487A (ja) * | 1984-09-12 | 1986-04-08 | Sumitomo Chem Co Ltd | カルバモイルアゾール誘導体およびそれを有効成分とする除草剤 |
EP0322779A3 (en) * | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
JP2729545B2 (ja) | 1991-06-05 | 1998-03-18 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料用の処理液及びそれを用いた処理方法 |
US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
SG63579A1 (en) * | 1992-12-21 | 1999-03-30 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
WO1994020473A1 (en) * | 1993-03-11 | 1994-09-15 | Yamanouchi Pharmaceutical Co., Ltd. | Compound with vasopressin antagonism |
CA2118985A1 (en) * | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Heterocyclic inhibitors of farnesyl protein transferase |
US5441952A (en) * | 1993-04-05 | 1995-08-15 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5843941A (en) | 1993-05-14 | 1998-12-01 | Genentech, Inc. | Ras farnesyl transferase inhibitors |
CA2170766A1 (en) * | 1993-11-05 | 1995-05-11 | Gary Louis Bolton | Substituted di- and tripeptide inhibitors of protein:farnesyl transferase |
JPH10500688A (ja) * | 1994-05-20 | 1998-01-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル−タンパク質トランスフェラーゼ阻害剤 |
WO1996000730A1 (en) * | 1994-06-29 | 1996-01-11 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
AU8872198A (en) | 1997-08-29 | 1999-03-22 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
-
1997
- 1997-02-20 US US08/802,329 patent/US6011029A/en not_active Expired - Lifetime
- 1997-02-24 SK SK1173-98A patent/SK286568B6/sk not_active IP Right Cessation
- 1997-02-24 KR KR1019980706651A patent/KR100522983B1/ko not_active IP Right Cessation
- 1997-02-24 CZ CZ0269698A patent/CZ299762B6/cs not_active IP Right Cessation
- 1997-02-24 GE GEAP19974460A patent/GEP20022616B/en unknown
- 1997-02-24 WO PCT/US1997/002920 patent/WO1997030992A1/en not_active Application Discontinuation
- 1997-02-24 RO RO98-01326A patent/RO121118B1/ro unknown
- 1997-02-24 HU HU9902016A patent/HUP9902016A3/hu not_active Application Discontinuation
- 1997-02-24 EE EE9800262A patent/EE04309B1/xx not_active IP Right Cessation
- 1997-02-24 EP EP20040016347 patent/EP1481975A1/en not_active Withdrawn
- 1997-02-24 IL IL14190897A patent/IL141908A/xx not_active IP Right Cessation
- 1997-02-24 IL IL12419797A patent/IL124197A/xx not_active IP Right Cessation
- 1997-02-24 PL PL328868A patent/PL191502B1/pl not_active IP Right Cessation
- 1997-02-24 JP JP53039597A patent/JP4115529B2/ja not_active Expired - Fee Related
- 1997-02-24 UA UA98084564A patent/UA52642C2/uk unknown
- 1997-02-24 CA CA002239187A patent/CA2239187C/en not_active Expired - Fee Related
- 1997-02-24 RU RU98117798/04A patent/RU2225405C2/ru not_active IP Right Cessation
- 1997-02-24 CN CNB971925356A patent/CN100376569C/zh not_active Expired - Fee Related
- 1997-02-24 AU AU21366/97A patent/AU718676B2/en not_active Ceased
- 1997-02-24 EP EP97906761A patent/EP0892797A4/en not_active Withdrawn
- 1997-02-24 NZ NZ330287A patent/NZ330287A/xx not_active IP Right Cessation
- 1997-02-24 BR BR9707614A patent/BR9707614A/pt not_active IP Right Cessation
- 1997-03-05 TW TW086102668A patent/TW496863B/zh not_active IP Right Cessation
-
1998
- 1998-06-04 LV LVP-98-129A patent/LV12150B/lv unknown
- 1998-08-25 NO NO19983892A patent/NO319395B1/no not_active IP Right Cessation
- 1998-08-28 BG BG102738A patent/BG64951B1/bg unknown
-
1999
- 1999-08-13 US US09/374,210 patent/US6455523B1/en not_active Expired - Fee Related
-
2001
- 2001-09-27 CN CN01141154A patent/CN1347881A/zh active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU718676B2 (en) | Inhibitors of farnesyl protein transferase | |
AU734721B2 (en) | Inhibitors of farnesyl protein transferase | |
US10053431B2 (en) | Tetrahydro-benzodiazepinones | |
AU735366B2 (en) | Inhibitors of farnesyl protein transferase | |
EP0918771A1 (en) | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | |
US6458783B1 (en) | Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase | |
US20030162965A1 (en) | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | |
LT4552B (lt) | Farnezilproteintransferazės inhibitoriai |